Duke University

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Duke University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Durham, NC, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1838</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://duke.edu/" target="_blank">https://duke.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Neuroinflammation](/mechanisms/neuroinflammation), [Clinical Trials](/clinical-trials)</td>
</tr>
<tr>
<td class="label">Departments</td>
<td>Department of Neurology, Department of Neuroscience, Center for Aging and Human Development</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>Bryan Alzheimer's Disease Research Center, Duke Movement Disorders Clinic, Duke-UNC Brain Aging Research Center</td>
</tr>
</table>

Duke University

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Duke University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Durham, NC, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1838</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://duke.edu/" target="_blank">https://duke.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Neuroinflammation](/mechanisms/neuroinflammation), [Clinical Trials](/clinical-trials)</td>
</tr>
<tr>
<td class="label">Departments</td>
<td>Department of Neurology, Department of Neuroscience, Center for Aging and Human Development</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>Bryan Alzheimer's Disease Research Center, Duke Movement Disorders Clinic, Duke-UNC Brain Aging Research Center</td>
</tr>
</table>

Duke University

Overview

Duke University is a premier private research institution located in Durham, NC, USA["@duke2026"]. The institution has established itself as a major force in neurodegenerative disease research through its Department of Neurology, Department of Neuroscience, and specialized research centers. Duke's neurodegeneration research programs span [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and related conditions.

Duke University hosts numerous researchers tracked in the NeuroWiki database and maintains multiple departments and centers dedicated to neuroscience and aging research["@duke2026a"]. The institution's research programs combine basic science investigation with clinical translation, advancing understanding of disease mechanisms, biomarkers, and therapeutic interventions.

With over $1.5 billion in annual research funding, Duke ranks among the nation's top research universities. The Medical Center, which includes the School of Medicine and Duke University Health System, provides an integrated environment for translating basic science discoveries into clinical applications.

History and Development

Duke University was founded in 1838 as Brown's Schoolhouse, a small school in Randolph County, North Carolina. The institution moved to Durham in 1892 and was renamed Trinity College before becoming Duke University in 1924 following a significant endowment from Washington Duke.

The Bryan Alzheimer's Disease Research Center was established in 1985 as one of the original NIA-funded ADRCs[@bryan1985]. This center has been instrumental in advancing understanding of Alzheimer's disease and related dementias. Over its four decades of operation, the Bryan ADRC has enrolled thousands of participants in longitudinal studies and clinical trials.

The Department of Neurology has grown from a small academic unit to one of the nation's leading neurology programs. Key milestones include:

• 1985: Bryan ADRC established
• 1990s: Movement Disorders Division founded
• 2000s: Center for Aging and Human Development launched
• 2010s: Neuroimaging Core established
• 2020s: Precision medicine initiative launched

Research Programs

Bryan Alzheimer's Disease Research Center

The Bryan ADRC is one of the original NIA-funded Alzheimer's Disease Research Centers, established in 1985. The center focuses on:

• Early detection and diagnosis of AD
• Biomarker development and validation[@blennow2019]
• Clinical trials for new therapeutics
• Training the next generation of AD researchers
• Understanding racial disparities in AD

Duke Movement Disorders Division

The Movement Disorders program at Duke is a leader in [Parkinson's disease](/diseases/parkinsons-disease) research and treatment:

• Deep brain stimulation (DBS) programming and outcomes[@donti2021]
• Levodopa-induced dyskinesia mechanisms
• [Alpha-synuclein](/proteins/alpha-synuclein) biology and targeting
• Genetic forms of PD (LRRK2, GBA, SNCA)[@goldman2019]
• Novel pharmacological interventions

Neuroimaging Research

Duke is home to advanced neuroimaging capabilities:

• PET imaging for amyloid and [tau](/proteins/tau) pathology[@rabinovici2017]
• Functional MRI for network connectivity
• Diffusion tensor imaging for white matter integrity
• Arterial spin labeling for cerebral blood flow

Key Research Areas

Neuroinflammation

Duke researchers investigate the critical role of [neuroinflammation](/mechanisms/neuroinflammation) in neurodegenerative diseases:

• Microglial activation states in AD and PD[@chen2019]
• [TREM2](/proteins/trem2-protein) and other innate immune receptors[@chen2018]
• [Complement system](/entities/complement-system) involvement in synapse loss[@martinez2019]
• Peripheral immune-brain interactions
• Therapeutic targeting of neuroinflammation

Biomarker Development

Duke's biomarker research includes:

• CSF and blood-based AD biomarkers ([Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), neurofilament)[@schindler2019]
• Imaging biomarkers for disease progression
• Genetic risk profiling ([APOE](/proteins/apoe-protein), [TREM2](/genes/trem2) variants)[@strittmatter1996]
• Digital biomarkers (motor timing, speech analysis)

Therapeutic Trials

Duke actively participates in clinical trials for:

• Anti-amyloid antibodies ([lecanemab](/entities/lecanemab), donanemab)[@pang2019]
• Anti-[tau](/proteins/tau) therapies
• Neuroprotective agents[@parsons2013]
• Gene therapy approaches
• Symptomatic treatments for cognitive and motor symptoms

Key Researchers

| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Warren Strittmatter | 75 | Alzheimer's Disease, Amyloid, [APP](/entities/app-protein)[@strittmatter1996] |
| Michael Lutz | 45 | Neuroinflammation, [Microglia](/cell-types/microglia-neuroinflammation), [TREM2](/proteins/trem2)[@chen2018] |
| John Ervin | 40 | Movement Disorders, Parkinson's Disease[@kalia2015] |
| Jeffrey Covey | 35 | Cognitive Disorders, Clinical Trials |

Warren Strittmatter Laboratory

Dr. Warren Strittmatter's laboratory has made seminal contributions to understanding Alzheimer's disease pathogenesis. His work on apolipoprotein E and its role in amyloid deposition established new paradigms in AD research. Current research focuses on:

• APP processing and amyloidogenesis
• Apolipoprotein E biology in the brain
• Novel therapeutic targets for AD

Michael Lutz Laboratory

Dr. Michael Lutz leads one of the premier neuroinflammation programs in the country. His work on TREM2 and microglial biology has illuminated the role of innate immunity in neurodegeneration. Current projects include:

• TREM2 signaling pathways in AD
• Microglial activation states and disease progression
• Development of immunomodulatory therapeutics

Movement Disorders Program

Led by Dr. John Ervin, Duke's Movement Disorders program provides comprehensive care for patients with Parkinson's disease and related disorders. The program combines clinical excellence with cutting-edge research in:

• Deep brain stimulation optimization
• Novel pharmacological treatments
• Genetic forms of PD[@goldman2019]
• Levodopa-induced complications

Clinical Trials

Duke actively recruits for neurodegenerative disease clinical trials. Current studies include:

• Anti-amyloid immunotherapy trials for early AD[@pang2019]
• Novel disease-modifying therapies for PD
• Neuroprotective interventions for ALS
• Biomarker validation studies

Collaborations

Duke maintains active collaborations with:

• National Institute on Aging: Alzheimer's Disease Research Centers Network
• Michael J. Fox Foundation: Parkinson's disease research
• Alzheimer's Association: International research programs
• Parkinson's Foundation: Center of Excellence network
• University of North Carolina: Duke-UNC Brain Aging Research Center

Regional Partnerships

The Research Triangle of North Carolina, comprising Duke, UNC-Chapel Hill, and NC State University, provides a unique environment for interdisciplinary collaboration. The Duke-UNC Brain Aging Research Center represents a particularly strong partnership, combining the expertise of both institutions in aging and neurodegeneration research.

Funding and Grants

Duke researchers maintain substantial grant funding from multiple sources:

• National Institute on Aging (NIA): Major funding for Bryan ADRC and related projects
• National Institute on Neurological Disorders and Stroke (NINDS): Parkinson's disease and ALS research
• Michael J. Fox Foundation: Parkinson's disease clinical trials and biomarker studies
• Alzheimer's Association: Research grants and fellowship support
• Department of Defense: Traumatic brain injury and neurodegeneration research

Institutional Rankings and Recognition

Duke's neuroscience and neurology programs consistently rank among the top in the United States:

• Neurology program ranked in top 20 nationally by U.S. News & World Report
• School of Medicine ranks in top 15 for research funding from NIH
• Bryan ADRC recognized as a leading center for neurodegeneration research

Facilities

Duke maintains state-of-the-art research facilities for neurodegenerative disease research:

• Bryan ADRC Clinical Core: Longitudinal patient cohort and biorepository
• Movement Disorders Center: Comprehensive clinical care and research
• Neuroimaging Core: PET, MRI, and CT facilities for neuroimaging[@poltis2015]
• Biomarker Laboratory: CSF and blood biomarker analysis
• Stem Cell Core: iPSC generation and differentiation for disease modeling

Clinical Research Unit

The Duke Clinical Research Unit coordinates all clinical trials in neurodegeneration, providing:

• Phase I-III trial infrastructure
• Regulatory support and compliance
• Data management and statistical analysis
• Patient recruitment and retention services

Biorepository

Duke maintains extensive biorepositories supporting neurodegenerative disease research:

• Over 10,000 CSF samples
• Blood samples from over 15,000 participants
• Brain tissue from the Bryan ADRC brain bank
• DNA samples for genetic studies

Training Programs

Duke offers comprehensive training in neurodegenerative disease research:

• Neurology Residency: ACGME-accredited training program
• Movement Disorders Fellowship: Subspecialty training for neurologists
• Behavioral Neurology Fellowship: Training in cognitive disorders
• Postdoctoral Training: Research fellowships in all neurodegeneration areas
• Graduate Programs: PhD training through the Department of Neuroscience

Training Outcomes

Duke's training programs have produced numerous leaders in the field:

• Over 100 graduates now leading research programs at academic institutions
• Many alumni in leadership positions in pharmaceutical companies
• Numerous recipients of prestigious awards and grants
• Multiple members of the National Academy of Sciences

Future Directions

Duke's future research priorities include:

• Precision Medicine: Genetic and biomarker-driven treatment approaches
• Early Detection: Identifying individuals before symptom onset[@jack2018]
• Multi-Modal Integration: Combining biomarkers, imaging, and clinical data
• Regenerative Medicine: Stem cell and gene therapy approaches
• Digital Health: Wearable sensors and remote monitoring

Emerging Research Themes

TREM2 Biology: Building on foundational discoveries about TREM2 variants and AD risk, Duke investigators are developing TREM2-targeting therapeutics and studying microglial activation in detail[@chen2018].

Alpha-Synuclein Therapeutics: Duke is leading efforts to develop disease-modifying therapies for Parkinson's disease, including immunotherapy and small molecule approaches.

Vascular Contributions: Understanding the intersection between cerebrovascular disease and neurodegeneration is a growing focus, with implications for both understanding disease mechanisms and developing prevention strategies[@jorgensen2019].

Digital Phenotyping: Duke is at the forefront of integrating digital health technologies into neurodegeneration research, including smartphone-based assessments and wearable sensors.

External Links

• Official Website: [https://duke.edu/](https://duke.edu/)
• Department of Neurology: [https://neurology.duke.edu/](https://neurology.duke.edu/)
• Bryan ADRC: [https://neurology.duke.edu/bryan-adrc](https://neurology.duke.edu/bryan-adrc)
• Movement Disorders: [https://neurology.duke.edu/divisions/movement-disorders](https://neurology.duke.edu/divisions/movement-disorders)

See Also

• [Researchers and Institutions Index](/researchers)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)
• [Clinical Trials](/clinical-trials)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)

References